ArticleCellular oncology (Dordrecht, Netherlands)2026
M
Article in Cellular oncology (Dordrecht, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe overexpression of long noncoding RNA (lncRNA) HULC is recognized as an important contributor to osteosarcoma (OS) progression. However, its precise roles and mechanisms in OS remain unclear, necessitating further investigation.
methodsThe expression levels of HULC, methyltransferase-like 3 (METTL3), TATA-box-binding protein-associated factor 15 (TAF15), and glucose transporter 1 (GLUT1) were measured using quantitative reverse transcription polymerase chain reaction (qRT-PCR). RNA in situ hybridization and subcellular localization analyses were conducted to determine the spatial distribution of HULC. Methylation of HULC by METTL3 was assessed using methylated RNA immunoprecipitation (MeRIP) assays. Functional assays, including CCK8 and transwell assays, were conducted to evaluate cell viability, migration, and invasion. Immunofluorescence staining of E-cadherin and N-cadherin was performed to assess the epithelial-mesenchymal transition (EMT). Glycolysis was evaluated through extracellular acidification rate, oxygen consumption rate, glucose uptake, lactate production, and ATP levels. Protein levels of glycolysis-related markers, TAF15, and GLUT1 were analyzed by Western blotting (WB). Xenograft and lung metastasis models were used to examine the roles of HULC and METTL3 in OS tumorigenesis and metastasis in vivo, and the interactions between TAF15 and HULC or GLUT1 were investigated using RNA immunoprecipitation (RIP) and RNA pull-down assays, while fluorescence in situ hybridization confirmed the co-localization of HULC and TAF15.
resultsElevated HULC expression was found to be correlated with poor prognosis in OS patients. In addition, METTL3-mediated m
conclusionM
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.